—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Medpace Holdings Inc (MEDP) — chart, structure and Closelooknet read

The Closelooknet read

Medpace runs clinical trials on behalf of drug and device makers, covering everything from early human-safety studies through to post-marketing follow-up. It designs trial protocols, manages regulatory filings, monitors sites, and analyses the resulting data across many disease areas.

Detail below: the desk's view, the earnings record, peers and the company snapshot; daily prices on the price-history tab. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for MEDP, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 46/100 · S&P 500 fund at 49, above its 200-day averageEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-11-04
  • Factor regime Defensive rotation — low-vol leading, regime-change watchMomentum against low volatility (SPMO / SPLV): below its 50-day trend, 73th percentile of the window, -21.7% over 20 sessions. Factor regime → 2026-11-04
  • Sector × region Health care in US: +5.5% week · +13.5% month · +15.8% quarter · +29.7% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-11-04
  • Sovereign pressure Index -1.79 · down 2.53 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-11-04
How it trades on rate days beta 0.25 to TLT · on the worst bond days it held up better than the market

How it trades on rate days

How MEDP has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.25 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), Medpace Holdings Inc moved 0.25% on average · correlation 0.05 · higher than 18% of US names
  • Beta, last 3 months −0.30 less rate-sensitive lately than over the year
  • On the 10 worst bond days −0.31% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +0.56% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Diagnostics & Research · US · 8 names with week and year-to-date

Peer group

Diagnostics & Research · US

Names in the same industry from the Closelooknet universe; scored names rank on their Closelooknet score, the rest on trend state.

Compared against MEDP on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Medpace Holdings Inc

MEDP in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Medpace runs clinical trials on behalf of drug and device makers, covering everything from early human-safety studies through to post-marketing follow-up. It designs trial protocols, manages regulatory filings, monitors sites, and analyses the resulting data across many disease areas. The company also runs its own laboratory, imaging and cardiac-monitoring services that feed straight into those trials. It is based in Cincinnati and serves pharmaceutical, biotechnology and medical-device sponsors worldwide.
Where it sits in the stack
Medpace carries no seat in Closelooknet's index. Inside our universe it sits in the Healthcare sector, grouped with US-listed diagnostics-and-research names for scoring rather than placed against any build-out layer.
Who it is priced against
Closelooknet's peer group groups it with other scored US healthcare names, chosen by sector and country rather than by business model — argenx, BeiGene, Globus Medical, Regeneron, Veeva Systems, Vertex, Corcept Therapeutics and IDEXX Laboratories. The market also names IQVIA as a comparable contract-research operator.
Why Closelooknet tracks it
Medpace carries a Closelooknet score, with momentum the strongest module and valuation the weakest; it holds no index seat and has not yet drawn a quote in the diary's editions.
What the diary watches
The diary watches whether momentum holds as the shares sit some way below their high, and whether the valuation gap to the rest of Closelooknet's Healthcare peer group narrows or widens from here.

Medpace Holdings Inc (MEDP) trades on US exchanges, classified under Healthcare.

The Closelooknet company score reads 62/100 composite (momentum 88, quality 74, valuation 25) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 4 analyst actions on the wire · latest: price target by BMO Capital, 2026-10-26

The Street on this name

Analyst actions and the latest print for MEDP from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target BMO Capital — target 670 from 600 Target raised to $670 from $600 (+0.2% to spot) 2026-10-26
  • Price target Truist — target 633 from 609 Target raised to $633 from $609 (-3.5% to spot) 2026-10-23
  • Price target UBS — target 700 from 673 Target raised to $700 from $673 (+5.6% to spot) 2026-10-23

4 actions on the analyst wire since 2026-08-13: 4 target changes. Analyst wire → · Earnings wire →

Dividends and capital return no distribution in twelve months · buybacks 917 m USD in FY2025

Dividends and capital return

What MEDP pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Buybacks, FY2025 917 m USD 4.9% of today's market value
  • Share count −7.8% in FY2025 35 m USD of stock-based compensation in the year
  • Capital returned 917 m USD · 135% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-11-05

Quick answers

What is Medpace Holdings Inc (MEDP)?

Medpace Holdings Inc trades as MEDP on the US exchange (US) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-11-05.

Is MEDP in a Closelooknet index?

Not currently — Medpace Holdings Inc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-11-05.

What is Medpace Holdings Inc's Closelooknet composite score?

62 out of 100, with momentum 88, quality 74 and valuation 25 sub-scores, as of 2026-11-05. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does MEDP trade against its moving averages?

Medpace Holdings Inc trades 5.7% above its 50-day and 23.9% above its 200-day moving average (2.0% above its 20-day). As of 2026-11-04 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Medpace Holdings Inc compare with its peers?

Against its peer group (Diagnostics & Research · US), Medpace Holdings Inc (MEDP) sits 5.4% below its 52-week high, 5.7% above its 50-day average; Guardant Health Inc (GH) is 11.8% below, Natera Inc (NTRA) is 11.2% below, CareDx Inc (CDNA) is 5.5% below, as of 2026-11-04. Put any of them next to MEDP in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Medpace Holdings Inc trade when bond yields rise?

Over the past year Medpace Holdings Inc had a beta of 0.25 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 18% of US names. On the 10 sessions in which long bonds fell most it moved −0.31% on average, against −0.74% for the S&P 500. As of 2026-11-04; The "How it trades on rate days" block on this page carries the lines.

What does Medpace Holdings Inc do?

Medpace runs clinical trials on behalf of drug and device makers, covering everything from early human-safety studies through to post-marketing follow-up. It designs trial protocols, manages regulatory filings, monitors sites, and analyses the resulting data across many disease areas. The company also runs its own laboratory, imaging and cardiac-monitoring services that feed straight into those trials. Closelooknet's peer group groups it with other scored US healthcare names, chosen by sector and country rather than by business model — argenx, BeiGene, Globus Medical, Regeneron, Veeva Systems, Vertex, Corcept Therapeutics and IDEXX Laboratories. The market also names IQVIA as a comparable contract-research operator. (Company snapshot of 2026-09-17.)

Where does Medpace Holdings Inc sit in the AI build-out?

Medpace carries no seat in Closelooknet's index. Inside our universe it sits in the Healthcare sector, grouped with US-listed diagnostics-and-research names for scoring rather than placed against any build-out layer. Medpace carries a Closelooknet score, with momentum the strongest module and valuation the weakest; it holds no index seat and has not yet drawn a quote in the diary's editions. (Company snapshot of 2026-09-17.)

Does Medpace Holdings Inc pay a dividend?

No cash distribution shows in Medpace Holdings Inc’s price series over the last three years. In fiscal 2025 the company bought back 917 m USD of its own shares, 135% of that year’s free cash flow. The share count fell 7.8% over the fiscal year. As of 2026-11-04; the "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Medpace Holdings Inc recently?

The most recent analyst action on Medpace Holdings Inc on the Closelooknet wire is a price target by BMO Capital on 2026-10-26 (target 670 from 600). 4 actions on the analyst wire since 2026-08-13: 4 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for MEDP, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

How to use this chart

Toolbar

  • Range — 1M to MAX on daily closes. 1D/5D switch a US stock cell to 5-minute intraday bars; index and foreign cells fall back to 1M daily with a note.
  • Grid — 1×1 up to 2×2. Cells are synchronized: pan or zoom one and the others follow the same dates; the crosshair tracks across all of them. 4 INDICES loads Rubin · HALO · AEI · AW40 side by side.
  • Type / Scale — OHLC, line or area; linear or log price axis.

Picking a series

  • Tap the box in a cell's header to browse every Closelooknet series — headline indices, sub-indices, sectors, layers of all six families — plus the constituents.
  • Or type any ticker (NVDA, 7203.T, ASML.AS …) and press Enter — it charts in the cell straight from our data lake.

Studies

  • Overlays / Oscillators rows toggle the standard set (SMA, Bollinger, RSI, MACD …) per cell.
  • Levels (stock cells) draws the structure engine's support lines — regression bands, pivot cluster, SMA-200, the active fib zone.

Drawing

  • Tap a tool (Trend, Ray, H-Line, Fib, Channel, Rect, Note), then tap the chart once per point — the shape follows your finger or cursor between taps. The chart stops panning while a tool is armed; tap the tool again to release.
  • Drawings save per symbol in this browser and travel between the terminal and the asset page.
  • Delete key removes the selected drawing · Escape cancels a half-placed one · Clear wipes the symbol.

Wave counts

  • Wave places an Elliott count: tap the origin, then each wave end. Press Enter to stop early (inside wave 3 is fine) — dotted ghost targets sketch the remaining waves at guideline ratios.
  • On stocks the scanner's machine count appears automatically in grey — it is fully editable: drag any point, double-tap a label to remove it, Delete to dismiss it for good, Adopt to bring the machine's proposal back.
  • The sequence picker switches 1-5 / A-B-C / A-E / W-X-Y-Z; 1 2 3 cycles the degree; Subdiv starts a one-degree-smaller child count inside a wave.

Sharing

  • Card exports the cell as a branded PNG — chart, drawings and levels exactly as shown.

Related in the Closelooknet universe

then Diagnostics & Research. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.